WO2001049673A2 - Compounds and methods for modulation of estrogen receptors - Google Patents

Compounds and methods for modulation of estrogen receptors Download PDF

Info

Publication number
WO2001049673A2
WO2001049673A2 PCT/US2000/035671 US0035671W WO0149673A2 WO 2001049673 A2 WO2001049673 A2 WO 2001049673A2 US 0035671 W US0035671 W US 0035671W WO 0149673 A2 WO0149673 A2 WO 0149673A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
animal
effective amount
bone
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/035671
Other languages
French (fr)
Other versions
WO2001049673A3 (en
Inventor
Shripad S. Bhagwat
Jeffrey A. Mckie
Sak Khammungkhune
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signal Pharmaceuticals LLC
Original Assignee
Signal Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/492,939 external-priority patent/US6291456B1/en
Priority claimed from US09/611,156 external-priority patent/US6331562B1/en
Priority to KR1020027008569A priority Critical patent/KR20020075388A/en
Priority to AU30771/01A priority patent/AU781282B2/en
Priority to AT00990966T priority patent/ATE289300T1/en
Priority to HK04101233.1A priority patent/HK1058521B/en
Priority to CA002396059A priority patent/CA2396059A1/en
Priority to DK00990966T priority patent/DK1246814T3/en
Application filed by Signal Pharmaceuticals LLC filed Critical Signal Pharmaceuticals LLC
Priority to DE60018215T priority patent/DE60018215T2/en
Priority to JP2001550213A priority patent/JP2003519219A/en
Priority to EP00990966A priority patent/EP1246814B1/en
Priority to IL15046300A priority patent/IL150463A0/en
Publication of WO2001049673A2 publication Critical patent/WO2001049673A2/en
Publication of WO2001049673A3 publication Critical patent/WO2001049673A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compounds that modulate gene expression through the estrogen receptor (ER) are disclosed having formula (I), as well as pharmaceutical compositions containing the same wherein R1, R2, R3, n and p are as defined here. In a specific embodiment, the compounds are selective modulators for ER-β over ER-α. Methods are also disclosed for modulating ER-β in cells and/or tissues expressing the same, including cells and/or tissues that preferentially express ER-β. More generally, methods for treating estrogen-related conditions are also disclosed, including conditions such as breast cancer, testicular cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, urinary incontinence, hairloss, cataracts, natureal hormonal imbalances, and adverse reproductive effects associated with exposure to environmental chemicals.

Claims

54CLAIMS
A compound having the structure:
Figure imgf000056_0001
eoisomer, prodrug or pharmaceutically acceptable salt thereof, wherein:
« is 0, 1 , 2, 3 or 4; p is 0;
R, is an unsubstituted or substituted C6.,2aryl, C7.12arylalky, C3.12heterocycle or C4., 6heterocyclealky 1 ;
R2 is NRgR*, wherein R, and Rb are independently hydrogen, C,.galkyl, C^aryl, or heterocycle, and wherein R,, and Rb are optionally substituted with up to three substituents independently selected from C-^alkyl, halogen, C-^alkoxy, hydroxy and carboxyl; or R2 is a heterocyclic ring ofthe following structure:
Figure imgf000056_0002
wherein 55 m, and m2 are independently 0, 1 or 2, and both m, and m2 are not O, A is CH2, O, S or NH,
Z represents 0, 1,
2 or 3 heterocyclic ring substituents selected from halogen, C,.8alkyl, C6.I2aryl, C7.I2arylalky, C3.]2heterocycle, or C4.,6heterocyclealkyl, and wherein any hydrogen atom on the heterocyclic ring may, taken together with a hydrogen atom on an adjacent atom of the heterocylic ring, form a double bond; R3 is hydrogen, R4, C(=O)R4, C(=O)OR4, CONHR4, CONR4R5, or SO2NR5R5; R4 and R5 are independently C,.8alkyl, .-.-aryl, C7.12aralkyl, or a five- or six- membered heterocycle containing up to two heteroatoms selected from O, NR^ and S(O)9, wherein each of the above groups are optionally substituted with one to three substituents independently selected from R7 and q is 0, 1 or 2; R<-. is hydrogen or C alkyl; and
R7 is hydrogen, halogen, hydroxy, C,.6alkyl, CMalkoxy, C acyloxy, C thio, C alkylsulfinyl, C alkylsulfonyl, (hydroxy)CMalkyl, C^aryl, C7_ 12aralkyl, COOH, CN, CONHOR8, SO2NHR8, NH2, C alkylamino, C dialkylamino, NHSO2R8, NO2, or a five- or six-membered heterocycle, where each occurrence of R8 is independently C-^alkyl.
The compound of claim 1 wherein R, is an unsubstituted or substituted
Cβ-πaryl-
3. The compound of claim 2 wherein R, is an unsubstituted or substituted phenyl.
4. The compound of claim 3 wherein R, is unsubstituted phenyl. 56
5. The compound of claim 3 wherein R, is substituted phenyl.
6. The compound of claim 5 wherein R, is 4-halophenyl, 4-methylphenyl, 4-hydroxyphenyl, 4-trifluorophenyl, 3-halophenyl, 2-halophenyl, 2,4-dihalophenyl, 3,4- dihalophenyl, wherein halo is fluoro, chloro, bro o or iodo.
7. The compound of claim 1 wherein R, is an unsubstituted or substituted heteroaryl.
8. The compound of claim 7 wherein R, is substituted or unsubstituted pyridinyl or thiophenyl.
9. The compound of claim 1 wherein R, is an unsubstituted or substituted C7.12arylalkyl.
10. The compound of claim 9 wherein R, is an unsubstituted or substituted benzyl.
11. The compound of claim 1 wherein R, is an unsubsituted or substituted C3.I2heterocycle or C4.I6heterocyclealkyl.
12. The compound of claim 1 wherein n is 2.
13. The compound of claim 1 wherein « is 0, 1, 3 or 4.
14. The compound of claim 1 wherein R3 is hydrogen.
15. The compound of claim 1 wherein R3 is C(=O)(C,.8alkyl) or C(=O)(C6.12aryl). 57
16. The compoimd of claim 1 wherein R3 is C(=O)O(C,.8alkyl), SO2NH2 or
CONH2.
17. The compound of claim 1 wherein R2 is a heterocyclic ring of the following structure:
Figure imgf000059_0001
18. The compound of claim 17 wherein m, and m2 are 1.
19. The compound of claim 18 wherein A is CH2.
20. The compound of claim 19 wherein R2 is piperdin- 1 -yl.
21. The compound of claim 18 wherein A is O.
22. The compound of claim 21 wherein R2 is morpholin-4-yl.
23. The compound of claim 17 wherein m, is 1 and m2 is 0.
24. The compound of claim 23 wherein A is CH2 and R2 is imidazolidin-2- yl substituted with 0 or 1 Z substituents.
25. The compound of claim 17 wherein R2 is imidazol-1-yl or imidazol-2- yl substituted with 0 or 1 Z substituents.
26. The compound of claim 1 wherein the R2-(CH2)n-O- moiety is attached at the 4-position ofthe phenyl ring. 58
27. The compound of claim 1 wherein the R2-(CH2)n-O- moiety is attached at the 3-position ofthe phenyl ring.
28. The compound of claim 1 having the structure:
Figure imgf000060_0001
29. The compound of claim 1 having the structure:
Figure imgf000060_0002
wherein X represents one or more phenyl substituents.
30. The compound of claim 28 having the structure:
Figure imgf000060_0003
59
31. The compound of claim 29 having the structure:
Figure imgf000061_0001
32. The compound of claim 31 having the structure:
Figure imgf000061_0002
wherein X is halogen.
33. A pharmaceutical composition comprising a compound of claim 1 in combination with a pharmaceutically acceptable carrier or diluent.
34. A method for inhibiting a cytokine in an animal in need thereof, comprising administering to the animal an effective amount ofthe composition of claim 33.
35. The method of claim 34 wherein the cytokine is IL-6.
36. The method of claim 34 wherein the cytokine is GM-CSF. 60
37. A method for modulating ER-β in a cell expressing ER-β, comprising contacting the cell with an effective amount of a compound of claim 1.
38. The method of claim 37 wherein the cell preferentially expresses ER-β over ER-α.
39. The method of claim 38 wherein the cell is of bone, bladder, uterus, ovary, prostate, testis, epididymis, gastrointestinal tract, kidney, breast, eye, heart, vessel wall, immune system, lung, pituitary, hippocampus or hypothalamus cell.
40. A method for modulating ER-β in tissue expressing ER-β, comprising contacting the tissue with an effective amount of a compound of claim 1.
41. The method of claim 40 wherein the tissue preferentially expresses ER-β over ER-α.
42. The method of claim 41 wherein the tissue is tissue of bone, bladder, uterus, ovary, prostate, testis, epididymis, gastrointestinal (GI) tract, kidney, breast, eye, heart, vessel wall, immune system, lung, pituitary, hippocampus or hypothalamus.
43. A method for treating an estrogen-related condition, comprising administering to an animal in need thereof an effective amount of a pharmaceutical composition of claim 33.
44. The method of claim 43 wherein the estrogen-related condition is breast cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, prostate cancer, menopausal syndromes, type-II diabetes, Alzheimer's disease, urinary incontinence, GI tract conditions, spermatogenesis, vascular protection after injury, endometriosis, learning and memory, CNS effects, plasma lipid levels, acne, hirsutism, solid cancers, multiple myeloma, lymphoma, hairloss, cataracts, natural hormonal imbalances, or adverse reproductive effects associated with exposure to environmental chemicals. 61
45. A method for treating a bone-resorbing disease in an animal in need thereof, comprising administering to the animal an effective amount ofthe composition of claim 33.
46. The method of claim 39 wherein the bone-resorbing disease is osteoporosis.
47. The method of claim 39 wherein the bone-resorbing disease is metastatic bone cancer, osteolytic lesions with an orthopedic implant, Paget's disease, or bone loss associated with hyperparathyroidism.
48. A method for treating cancer associated with IL-6 in an animal in need thereof, comprising administering to the animal an effective amount ofthe composition of claim 35.
49. The method of claim 48 wherein the cancer is breast cancer, prostrate cancer, colon cancer, endometrial cancer, multiple myeloma, renal cell carcinoma, or cervical carcinoma.
50. A method for treating arthritis in an animal in need thereof, comprising administering to the animal an effective amount of the composition of claim 33.
51. The method of claim 50 wherein the arthritis is rheumatoid arthritis.
52. A method for modulating gene expression in a cell expressing ER-β, comprising contacting the cell with an effective amount of a compound of claim 1.
53. The method of claim 52 wherein the cell is of bone, bladder, uterus, ovary, prostate, testis, epididymis, gastrointestinal tract, kidney, breast, eye, heart, vessel wall, immune system, lung, pituitary, hippocampus or hypothalamus. 62
54. The compound of claim 1, having the structure:
Figure imgf000064_0001
or a pharmaceutically acceptable salt thereof.
55. The compound of claim 1, having the structure:
Figure imgf000064_0002
or a pharmaceutically acceptable salt thereof.
56. The compound of claim 1, having the structure:
Figure imgf000064_0003
or a pharmaceutically acceptable salt thereof. 63
57. The compound of claim 1 , having the structure:
Figure imgf000065_0001
or a pharmaceutically acceptable salt thereof.
58. The compound of claim 1, having the structure:
Figure imgf000065_0002
or a pharmaceutically acceptable salt thereof.
59. A pharmaceutical composition comprising a therapeutically effective amount of a compound of any one of claims 54-57 or 58 and a pharmaceutically acceptable carrier or diluent.
60. A method for inhibiting a cytokine in an animal in need thereof, comprising administering to the animal an effective amount ofthe composition of claim 59.
61. The method of claim 60 wherein the cytokine is IL-6.
62. The method of claim 60 wherein the cytokine is GM-CSF. 64
63. A method for modulating ER-β in a cell expressing ER-β, comprising contacting the cell with an effective amount of a compound of any one of claims 54-57 or 58.
64. The method of claim 63 wherein the cell preferentially expresses ER-β over ER-α.
65. The method of claim 64 wherein the cell is of bone, bladder, uterus, ovary, prostate, testis, epididymis, gastrointestinal tract, kidney, breast, eye, heart, vessel wall, immune system, lung, pituitary, hippocampus or hypothalamus cell.
66. A method for modulating ER-β in tissue expressing ER-β, comprising contacting the tissue with an effective amount of a compound of any one of claims 54-57 or 58.
67. The method of claim 66 wherein the tissue preferentially expresses ER-β over ER-α.
68. The method of claim 67 wherein the tissue is tissue of bone, bladder, uterus, ovary, prostate, testis, epididymis, gastrointestinal (GI) tract, kidney, breast, eye, heart, vessel wall, immune system, lung, pituitary, hippocampus or hypothalamus.
69. A method for treating an estrogen-related condition, comprising administering to an animal in need thereof an effective amount of a pharmaceutical composition of claim 59.
70. The method of claim 69 wherein the estrogen-related condition is breast cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, prostate cancer, menopausal syndromes, type-II diabetes, Alzheimer's disease, urinary incontinence, GI tract conditions, spermatogenesis, vascular protection after injury, endometriosis, learning and memory, CNS effects, plasma lipid levels, acne, hirsutism, solid cancers, multiple myeloma, lymphoma, hairloss, cataracts, natural 65 hormonal imbalances, or adverse reproductive effects associated with exposure to environmental chemicals.
71. A method for treating a bone-resorbing disease in an animal in need thereof, comprising administering to the animal an effective amount ofthe composition of claim 59.
72. The method of claim 65 wherein the bone-resorbing disease is osteoporosis.
73. The method of claim 65 wherein the bone-resorbing disease is metastatic bone cancer, osteolytic lesions with an orthopedic implant, Paget's disease, or bone loss associated with hyperparathyroidism.
74. A method for treating cancer associated with IL-6 in an animal in need thereof, comprising administering to the animal an effective amount ofthe composition of claim 61.
75. The method of claim 74 wherein the cancer is breast cancer, prostrate cancer, colon cancer, endometrial cancer, multiple myeloma, renal cell carcinoma, or cervical carcinoma.
76. A method for treating arthritis in an animal in need thereof, comprising administering to the animal an effective amount ofthe composition of claim 59.
77. The method of claim 76 wherein the arthritis is rheumatoid arthritis.
78. A method for modulating gene expression in a cell expressing ER-β, comprising contacting the cell with an effective amount of a compound of any one of claims 54-57 or 58. 66
79. The method of claim 78 wherein the cell is of bone, bladder, uterus, ovary, prostate, testis, epididymis, gastrointestinal tract, kidney, breast, eye, heart, vessel wall, immune system, lung, pituitary, hippocampus or hypothalamus.
PCT/US2000/035671 1999-12-30 2000-12-29 Compounds and methods for modulation of estrogen receptors Ceased WO2001049673A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP00990966A EP1246814B1 (en) 1999-12-30 2000-12-29 Compounds and methods for modulation of estrogen receptors
IL15046300A IL150463A0 (en) 1999-12-30 2000-12-29 Compounds and methods for modulation of estrogen receptors
DE60018215T DE60018215T2 (en) 1999-12-30 2000-12-29 COMPOUNDS AND METHOD FOR MODULATING ESTROGEN RECEPTORS
AT00990966T ATE289300T1 (en) 1999-12-30 2000-12-29 COMPOUNDS AND METHODS FOR MODULATING ESTROGEN RECEPTORS
HK04101233.1A HK1058521B (en) 1999-12-30 2000-12-29 Compounds and methods for modulation of estrogen receptors
CA002396059A CA2396059A1 (en) 1999-12-30 2000-12-29 Compounds and methods for modulation of estrogen receptors
DK00990966T DK1246814T3 (en) 1999-12-30 2000-12-29 Compounds and Methods for Modulation of Estrogen Receptors
KR1020027008569A KR20020075388A (en) 1999-12-30 2000-12-29 Compounds and methods for modulation of estrogen receptors
AU30771/01A AU781282B2 (en) 1999-12-30 2000-12-29 Compounds and methods for modulation of estrogen receptors
JP2001550213A JP2003519219A (en) 1999-12-30 2000-12-29 Compounds and methods for modulating estrogen receptors

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US47577699A 1999-12-30 1999-12-30
US09/475,776 1999-12-30
US09/492,939 US6291456B1 (en) 1998-12-30 2000-01-27 Compounds and methods for modulation of estrogen receptors
US09/492,939 2000-01-27
US09/611,156 2000-07-06
US09/611,156 US6331562B1 (en) 1998-12-30 2000-07-06 Compounds and methods for modulation of estrogen receptors

Publications (2)

Publication Number Publication Date
WO2001049673A2 true WO2001049673A2 (en) 2001-07-12
WO2001049673A3 WO2001049673A3 (en) 2001-12-06

Family

ID=27413348

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/035671 Ceased WO2001049673A2 (en) 1999-12-30 2000-12-29 Compounds and methods for modulation of estrogen receptors

Country Status (13)

Country Link
EP (1) EP1246814B1 (en)
JP (1) JP2003519219A (en)
KR (1) KR20020075388A (en)
CN (1) CN1281598C (en)
AT (1) ATE289300T1 (en)
AU (1) AU781282B2 (en)
CA (1) CA2396059A1 (en)
DE (1) DE60018215T2 (en)
DK (1) DK1246814T3 (en)
ES (1) ES2238034T3 (en)
IL (1) IL150463A0 (en)
PT (1) PT1246814E (en)
WO (1) WO2001049673A2 (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1281710A1 (en) * 2001-08-03 2003-02-05 CHIESI FARMACEUTICI S.p.A. 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
EP1120114A3 (en) * 2000-01-12 2003-08-20 Pfizer Products Inc. Compositions and methods for treating conditions responsive to estrogen
WO2003089422A1 (en) * 2002-04-19 2003-10-30 Signal Pharmaceuticals, Inc. Benzopyranone compounds, compositions thereof, and methods of treatment therewith
WO2004101544A1 (en) * 2003-05-14 2004-11-25 Warner-Lambert Company Llc Benzyl sulfonamide derivatives as androgen receptor antagonists
EP1460969A4 (en) * 2001-11-29 2005-08-17 Gtx Inc Prevention and treatment of androgen-deprivation induced osteoporosis
US7091235B2 (en) 2002-10-15 2006-08-15 Signal Pharmaceuticals, Llc Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer
EP1450812A4 (en) * 2001-10-03 2007-03-28 Signal Pharm Inc Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis
US7217734B2 (en) 2001-11-19 2007-05-15 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
US7279499B2 (en) 2003-04-21 2007-10-09 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
WO2008002490A3 (en) * 2006-06-23 2008-06-26 Radius Health Inc Treatment of vasomotor symptoms with selective estrogen receptor modulators
AU2005202072B2 (en) * 2001-11-29 2008-10-23 Gtx, Inc. Prevention and treatment of androgen-deprivation induced conditions
US7442812B2 (en) 2003-04-21 2008-10-28 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US7674783B2 (en) * 2002-11-22 2010-03-09 Dimera Inc. Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease
CN105801543A (en) * 2016-04-18 2016-07-27 中国药科大学 4-arylamine-coumarin derivative and preparing method and medical application thereof
CN105801544A (en) * 2016-04-18 2016-07-27 中国药科大学 3-aryl-4-arylamine-coumarin derivative and preparing method and medical application thereof
US9555014B2 (en) 2010-05-12 2017-01-31 Radius Health, Inc. Therapeutic regimens
US9920044B2 (en) 2010-09-28 2018-03-20 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
US10071066B2 (en) 2014-03-28 2018-09-11 Duke University Method of treating cancer using selective estrogen receptor modulators
US10385008B2 (en) 2017-01-05 2019-08-20 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD1901-2HCL
US10420734B2 (en) 2014-03-28 2019-09-24 Duke University Method of treating cancer using selective estrogen receptor modulators
US11771682B2 (en) 2016-06-22 2023-10-03 Ellipses Pharma Ltd. AR+ breast cancer treatment methods

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1177787A3 (en) * 2000-07-28 2003-09-10 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating cataracts
AU2004274445A1 (en) * 2003-09-15 2005-03-31 Novartis Ag Benzopyranone compounds, compositions thereof, and methods of treatment therewith
CA2595472A1 (en) * 2005-01-21 2006-07-27 Janssen Pharmaceutica N.V. Novel coumarin derivatives as ion channel openers
CN106492204A (en) * 2016-12-27 2017-03-15 郑州郑先医药科技有限公司 One kind treats cataractous pharmaceutical composition
CN106727637A (en) * 2016-12-27 2017-05-31 郑州郑先医药科技有限公司 It is a kind of to treat Western medicine compound of cataract and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726202A (en) * 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
AU1367297A (en) * 1996-01-11 1997-08-01 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical comp osition for the treatment or prophylaxis of menopausal symptoms
US5883118A (en) * 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
JP2002533456A (en) * 1998-12-30 2002-10-08 シグナル ファーマシューティカルズ， インコーポレイテッド Compounds and methods for modulating estrogen receptors

Cited By (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1120114A3 (en) * 2000-01-12 2003-08-20 Pfizer Products Inc. Compositions and methods for treating conditions responsive to estrogen
EP1281710A1 (en) * 2001-08-03 2003-02-05 CHIESI FARMACEUTICI S.p.A. 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
EP1450812A4 (en) * 2001-10-03 2007-03-28 Signal Pharm Inc Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis
US7217734B2 (en) 2001-11-19 2007-05-15 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
EP2098247A3 (en) * 2001-11-29 2010-05-26 GTX, Inc. Prevention and treatment of androgen-deprivation induced loss of BMD or bone fractures
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
EP1460969A4 (en) * 2001-11-29 2005-08-17 Gtx Inc Prevention and treatment of androgen-deprivation induced osteoporosis
EP1574212A1 (en) * 2001-11-29 2005-09-14 GTX Inc. Prevention and treatment of androgen-deprivation induced hot flashes, decreased lean muscle mass, loss of libido or erectile dysfunction
EP1666033A1 (en) * 2001-11-29 2006-06-07 GTX, Inc. Prevention and treatment of androgen-deprivation induced osteoporosis
AU2005202072B2 (en) * 2001-11-29 2008-10-23 Gtx, Inc. Prevention and treatment of androgen-deprivation induced conditions
AU2002356928B2 (en) * 2001-11-29 2008-04-17 Gtx Inc. Prevention and treatment of androgen-deprivation induced osteoporosis
AU2003239155B2 (en) * 2002-04-19 2008-12-04 Novartis Ag Benzopyranone compounds, compositions thereof, and methods of treatment therewith
JP2006504629A (en) * 2002-04-19 2006-02-09 シグナル ファーマシューティカルズ，エルエルシー Benzopyranone compounds, compositions thereof and methods of treatment using the same
WO2003089422A1 (en) * 2002-04-19 2003-10-30 Signal Pharmaceuticals, Inc. Benzopyranone compounds, compositions thereof, and methods of treatment therewith
CN100436440C (en) * 2002-04-19 2008-11-26 信号药品公司 Benzopyrone compounds, compositions thereof, and methods of treatment thereof
EP1556374A4 (en) * 2002-10-15 2007-12-19 Signal Pharm Inc Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer
US7358274B2 (en) 2002-10-15 2008-04-15 Signal Pharmaceuticals, Llc Methods for treating or preventing cancer using Benzopyranone Compounds
US7091235B2 (en) 2002-10-15 2006-08-15 Signal Pharmaceuticals, Llc Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer
US7589119B2 (en) 2002-10-15 2009-09-15 Signal Pharmaceutical, Llc Methods for treating or preventing metastatic cancer using benzopyranone compounds
US7674783B2 (en) * 2002-11-22 2010-03-09 Dimera Inc. Estrogen beta receptor agonists to prevent or reduce the severity of cardiovascular disease
US7842822B2 (en) 2003-04-21 2010-11-30 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
US7585985B2 (en) 2003-04-21 2009-09-08 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
US7442812B2 (en) 2003-04-21 2008-10-28 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
US7279499B2 (en) 2003-04-21 2007-10-09 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
US7098340B2 (en) 2003-05-14 2006-08-29 Warner Lambert Company Llc Benzyl sulfonamide derivatives
WO2004101544A1 (en) * 2003-05-14 2004-11-25 Warner-Lambert Company Llc Benzyl sulfonamide derivatives as androgen receptor antagonists
WO2008002490A3 (en) * 2006-06-23 2008-06-26 Radius Health Inc Treatment of vasomotor symptoms with selective estrogen receptor modulators
US8933130B2 (en) 2006-06-23 2015-01-13 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
US9555014B2 (en) 2010-05-12 2017-01-31 Radius Health, Inc. Therapeutic regimens
US9920044B2 (en) 2010-09-28 2018-03-20 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
US10071066B2 (en) 2014-03-28 2018-09-11 Duke University Method of treating cancer using selective estrogen receptor modulators
US10420734B2 (en) 2014-03-28 2019-09-24 Duke University Method of treating cancer using selective estrogen receptor modulators
US11779552B2 (en) 2014-03-28 2023-10-10 Duke University Method of treating cancer using selective estrogen receptor modulators
US11951080B2 (en) 2014-03-28 2024-04-09 Duke University Method of treating cancer using selective estrogen receptor modulators
US12263142B2 (en) 2014-03-28 2025-04-01 Duke University Method of treating cancer using selective estrogen receptor modulators
CN105801544A (en) * 2016-04-18 2016-07-27 中国药科大学 3-aryl-4-arylamine-coumarin derivative and preparing method and medical application thereof
CN105801543A (en) * 2016-04-18 2016-07-27 中国药科大学 4-arylamine-coumarin derivative and preparing method and medical application thereof
CN105801543B (en) * 2016-04-18 2019-08-02 中国药科大学 4-arylamine-coumarin derivatives and their preparation methods and medical applications
US11771682B2 (en) 2016-06-22 2023-10-03 Ellipses Pharma Ltd. AR+ breast cancer treatment methods
US12329746B2 (en) 2016-06-22 2025-06-17 Ellipses Pharma Ltd AR+breast cancer treatment methods
US10385008B2 (en) 2017-01-05 2019-08-20 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD1901-2HCL

Also Published As

Publication number Publication date
IL150463A0 (en) 2002-12-01
ES2238034T3 (en) 2005-08-16
CN1437591A (en) 2003-08-20
EP1246814A2 (en) 2002-10-09
DE60018215T2 (en) 2006-02-09
AU781282B2 (en) 2005-05-12
AU3077101A (en) 2001-07-16
JP2003519219A (en) 2003-06-17
HK1058521A1 (en) 2004-05-21
CA2396059A1 (en) 2001-07-12
EP1246814B1 (en) 2005-02-16
KR20020075388A (en) 2002-10-04
WO2001049673A3 (en) 2001-12-06
CN1281598C (en) 2006-10-25
ATE289300T1 (en) 2005-03-15
DK1246814T3 (en) 2005-05-30
PT1246814E (en) 2005-07-29
DE60018215D1 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
EP1246814A2 (en) Compounds and methods for modulation of estrogen receptors
JP2003519219A5 (en)
JP2002533456A5 (en)
ES2298823T3 (en) DERIVATIVES OF THE OXYM OF (4-HYDROXYPHENYL) -1H-INDOL-3-CARBALDEHIDO AS STROGEN AGENTS.
Navidpour et al. Design, synthesis, and biological evaluation of substituted 2-alkylthio-1, 5-diarylimidazoles as selective COX-2 inhibitors
ES2277273T3 (en) OXYMATE DERIVATIVES OF ARIL-CARBALDEHIDO, AND ITS USE AS A ESTROGEN AGENT.
US7488831B2 (en) Process for producing 5-hydroxy-4-thiomethylpyrazole compound
HU222181B1 (en) Pyrrolo [2,3-d] pyrimidines, process for their preparation and pharmaceutical compositions containing them
JP2016155832A (en) Estrogen receptor modulator and use thereof
WO2013062344A1 (en) Hydroxamate derivatives for hdac inhibitor, and the pharmaceutical composition comprising thereof
ATE361748T1 (en) 1-(4-SULFAMYLPHENYL)-3-TRIFLUORMETHYL-5-ARYL-2-PYRAZOLINE AS CYCLOOXYGENASE-2 INHIBITORS
BG107877A (en) Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists
WO2000039120A3 (en) Compounds and methods for modulation of estrogen receptors
Farag et al. Synthesis and structure‐activity relationship studies of pyrazole‐based heterocycles as antitumor agents
US7138421B2 (en) Anti-androgenic pyrrolidines with tumor-inhibiting action
SK6042003A3 (en) 3-Arylindole derivatives and their use as CB2 receptor agonists
NZ518682A (en) 5-aryl-1H-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them
CA2927641A1 (en) Pyrazolopyrimidone or pyrrolotriazone derivatives, method of preparing same, and pharmaceutical applications thereof
CA2628747A1 (en) Combinations of hormone therapy agents and metalloprotease inhibitors for the treatment of cancer
Gineinah et al. Synthesis and Antiinflammatory Screening of Some Quinazoline and Quinazolyl‐4‐oxoquinazoline Derivatives
JP2006504629A5 (en)
EP1363903A1 (en) Indole derivatives and their use as gnrh antagonists
KR20090020694A (en) Glucocorticoid receptor modulators and methods of use thereof
JPH07242626A (en) Gastric acid secretion inhibitor and anti-ulcer agent
JP6470984B2 (en) Aromatase inhibitor and medicament containing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 150463

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2396059

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020027008569

Country of ref document: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 550213

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 30771/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000990966

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 008192227

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020027008569

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000990966

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2000990966

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 30771/01

Country of ref document: AU